Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Agus, 2000, A potential role for activated HER-2 in prostate cancer, Semin. Oncol., 27, 76 Agus, 2002, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, 2, 127, 10.1016/S1535-6108(02)00097-1 Aroian, 1990, The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily, Nature, 348, 693, 10.1038/348693a0 Arteaga, 2003, ErbB-targeted therapeutic approaches in human cancer, Exp. Cell Res., 284, 122, 10.1016/S0014-4827(02)00104-0 Burgess, 2003, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors, Mol. Cell, 12, 541, 10.1016/S1097-2765(03)00350-2 Carter, 1992, Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc. Natl. Acad. Sci. USA, 89, 4285, 10.1073/pnas.89.10.4285 Carter, 2000, Development of Herceptin, Breast Disease, 11, 103, 10.3233/BD-1999-11109 Cho, 2002, Structure of the extracellular region of HER3 reveals an interdomain tether, Science, 297, 1330, 10.1126/science.1074611 Cho, 2003, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 421, 756, 10.1038/nature01392 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639 Eigenbrot, 1993, X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling, J. Mol. Biol., 229, 969, 10.1006/jmbi.1993.1099 Falls, 2003, Neuregulins, Exp. Cell Res., 284, 14, 10.1016/S0014-4827(02)00102-7 Fendly, 1990, Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product, Cancer Res., 50, 1550 Ferguson, 2000, Extracellular domains drive homo- but not hetero-dimerization of erbB receptors, EMBO J., 19, 4632, 10.1093/emboj/19.17.4632 Ferguson, 2003, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization, Mol. Cell, 11, 507, 10.1016/S1097-2765(03)00047-9 Fry, 2003, Mechanism of action of erbB tyrosine kinase inhibitors, Exp. Cell Res., 284, 131, 10.1016/S0014-4827(02)00095-2 Garrett, 2002, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha, Cell, 110, 763, 10.1016/S0092-8674(02)00940-6 Garrett, 2003, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, Mol. Cell, 11, 495, 10.1016/S1097-2765(03)00048-0 Graus-Porta, 1997, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J., 16, 1647, 10.1093/emboj/16.7.1647 Groenen, 1997, A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer?, Biochemistry, 36, 3826, 10.1021/bi9614141 Hanks, 1995, Protein kinases 6. The eukaryotic protein kinase superfamily, FASEB J., 9, 576, 10.1096/fasebj.9.8.7768349 Holbro, 2003, The ErbB receptors and their role in cancer progression, Exp. Cell Res., 284, 99, 10.1016/S0014-4827(02)00099-X Hudziak, 1991, Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum, J. Biol. Chem., 266, 24109, 10.1016/S0021-9258(18)54400-8 Jorissen, 2003, Epidermal growth factor receptor, Exp. Cell Res., 284, 31, 10.1016/S0014-4827(02)00098-8 Kelley, 1992, Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments, Biochemistry, 31, 5434, 10.1021/bi00139a003 Livneh, 1985, The Drosophila EGF receptor gene homolog, Cell, 40, 599, 10.1016/0092-8674(85)90208-9 Mann, 2001, Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth, Gastroenterology, 120, 1713, 10.1053/gast.2001.24844 Mendoza, 2002, Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer, Cancer Res., 62, 5485 Molina, 2001, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res., 61, 4744 Murali, 1996, Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases, Proc. Natl. Acad. Sci. USA, 93, 6252, 10.1073/pnas.93.13.6252 Murshudov, 1997, Refinement of Macromolecular Structures by the Maximum-Likelihood Method, Acta Crystallogr. D, 53, 240, 10.1107/S0907444996012255 Navaza, 1994, AMoRe, Acta Crystallogr. A, 50, 157, 10.1107/S0108767393007597 Ogiso, 2002, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell, 110, 775, 10.1016/S0092-8674(02)00963-7 Olayioye, 2000, The ErbB signaling network, EMBO J., 19, 3159, 10.1093/emboj/19.13.3159 Paborsky, 1990, Mammalian cell transient expression of tissue factor for the production of antigen, Protein Eng., 3, 547, 10.1093/protein/3.6.547 Paik, 2000, HER2 as a predictor of therapeutic response in breast cancer, Breast Disease, 11, 91, 10.3233/BD-1999-11108 Ross, 1998, The HER-2/neu oncogene in breast cancer, Stem Cells, 16, 413, 10.1002/stem.160413 Schaefer, 1999, A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2, J. Biol. Chem., 274, 859, 10.1074/jbc.274.2.859 Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8 Slamon, 1987, Human breast cancer, Science, 235, 177, 10.1126/science.3798106 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Stamos, 2002, Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor, J. Biol. Chem., 277, 46265, 10.1074/jbc.M207135200 Stein, 2000, Evolutionary analysis of the ErbB receptor and ligand families, J. Mol. Evol., 50, 397, 10.1007/s002390010043 Vajdos, 2002, Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis, J. Mol. Biol., 320, 415, 10.1016/S0022-2836(02)00264-4 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719 Wadsworth, 1985, A Drosophila genomic sequence with homology to human epidermal growth factor receptor, Nature, 314, 178, 10.1038/314178a0 Ward, 2001, The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules, BMC Bioinformatics, 2, 4, 10.1186/1471-2105-2-4 Werther, 1996, Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1, J. Immunol., 157, 4986, 10.4049/jimmunol.157.11.4986 Yarden, 2001, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073